Aimee DeGaetano Joins Vastrax as Global Head of Commercial and Clinical Affairs

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

Leading Clinical Research Organization Strengthens Expertise in Neurovascular Field


ANDOVER, Mass.–(BUSINESS WIRE)–Vastrax, a premier full-service Contract Research Organization (CRO) with a mission to expedite the development of cutting-edge technologies in the vascular market, proudly announces the appointment of Aimee DeGaetano as the Global Head of Commercial and Clinical Affairs.

“Our dedication to accelerating advancements in the vascular sector is unwavering, and Aimee’s appointment reinforces this commitment,” said Ryan Bouchard, President and CEO of Vastrax. “Aimee’s expertise aligns seamlessly with our mission, and we are thrilled to have her lead our Global Commercial Strategy and Clinical Affairs. Aimee’s appointment comes at a crucial juncture in Vastrax’s journey as we continue to lead the way in neurovascular clinical trials. Her expertise will significantly contribute to our efforts in helping our clients advance ground-breaking technological solutions that have the potential to transform the lives of patients worldwide.”

Aimee is a registered dietician (RD) and holds a master’s in public health (clinical epidemiology). She is currently completing a doctorate in health science at Eastern Virginia Medical School. She has held various leadership roles in medical technology companies, focusing on clinical trials, medical affairs, and key opinion leader engagement. Her unique blend of skills perfectly aligns with Vastrax’s multifaceted approach to driving efficient technology approvals.

“I am honored to contribute to Vastrax’s pivotal role in assisting our clients to expedite the introduction of groundbreaking vascular technologies,” commented Aimee DeGaetano. “Together, we will fortify our commitment to clinical trials, integrating novel innovations, strategies and technologies to enhance patient care and improve outcomes.”

About Vastrax, Inc.

Vastrax is a cutting-edge full-service Contract Research Organization specializing in expediting the development of cutting-edge technologies in the vascular market. With an expert team possessing over 100 years of combined clinical, commercial, and regulatory experience, Vastrax is at the forefront of pioneering innovations, delivering transformative products to market efficiently. For more information please visit us at www.vastrax.com and follow us on LinkedIn.

Contacts

Tara DiMilia

908-369-7168

Tara.DiMilia@tmstrat.com

Staff

Recent Posts

KNoW Biological Receives FDA Breakthrough Device Designation

Atlanta-based firm to begin clinical trial on advanced warning seizure monitor ATLANTA, May 13, 2025…

1 minute ago

Wincomm Wins Best Choice Award at COMPUTEX 2025 for AI-Driven Surgical Panel PC

HSINCHU, May 13, 2025 /PRNewswire/ -- Wincomm, a global leader in medical-grade computing solutions, has…

1 minute ago

Fangzhou CEO Honored at 2025 VBEF Conference as Company Showcases AI Medical Innovations

SUZHOU, China, May 13, 2025 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader…

1 minute ago

For Labbit, Semaphore Solutions Recognized in the Gartner® Market Guide for Laboratory Information Management Systems

VICTORIA, BC, May 13, 2025 /PRNewswire/ - Semaphore Solutions, a leading provider of laboratory informatics…

2 minutes ago

GI Innovation and GI Biome Advance to the Semi-finals of XPRIZE Healthspan with Anti-Aging Potential of GI-102 and GIB-7 Combination Therapy

GI Innovation and GI Biome have been selected as a Top 40 semi-finalist in the XPRIZE Healthspan competition among…

6 hours ago

Tyra Biosciences to Participate at Upcoming Investor Conferences

CARLSBAD, Calif., May 12, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology…

12 hours ago